Clinical Trials Browser

Phase 1/2 × Hematologic Neoplasms × Brentuximab Vedotin × Clear all

NCT01620229 2014-04-21

Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Phase 1/2 Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms